Kolexia
Mazieres Julien Pneumologie
Mazieres Julien
Pneumologie
Hôpital Rangueil
Toulouse, France
886 Activités
4.1 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Adénocarcinome Métastase tumorale Mésothéliome Carcinomes Mésothéliome malin Adénocarcinome pulmonaire

Collaborateurs

Voir plus
Barlesi Fabrice
Barlesi Fabrice
Gustave-Roussy, Villejuif, France
Besse Benjamin
Besse Benjamin
Gustave-Roussy, Villejuif, France
Moro-Sibilot Denis
Moro-Sibilot Denis
Hôpital Nord Grenoble, La Tronche, France
Zalcman Gerard
Zalcman Gerard
Hôpital Bichat-Claude-Bernard, Paris, France

Industries

Voir plus
AstraZeneca
46 collaboration(s)
Dernière en 2023
MSD
23 collaboration(s)
Dernière en 2023
Amgen
20 collaboration(s)
Dernière en 2023
Roche
14 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1): A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)
Essai Clinique (Nuvalent Inc.)   07 mars 2024
Deleterious association between proton pump inhibitor and protein kinase inhibitor exposure and survival for patients with lung cancer: A nationwide cohort study.
Cancer treatment and research communications   29 février 2024
Combination of electromagnetic navigation and probe-based LASER endomicroscopy to guide non-solid nodules sampling: Results from the CELTICS 2 study.
Respiratory medicine and research   28 février 2024
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
Essai Clinique (Lilly)   27 février 2024
AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.
Essai Clinique (Unicancer)   26 février 2024
ARROW: A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Essai Clinique (Roche)   21 février 2024
Met Non Small Cell Cancer Registry (MOMENT): Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
Essai Clinique (Emd Serono)   19 février 2024
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Lung cancer (Amsterdam, Netherlands)   19 février 2024
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Essai Clinique (Pfizer)   14 février 2024
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced -Mutant Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   07 février 2024